Bernard Luke Flynn

This inventor holds 27 USPTO granted patents, plus 1 CIPO patent and 6 EPO patents, primarily in Anxiolytic Compounds. Top assignees: Bionomics Inc., Ironwood Pharmaceuticals, Inc., Beijing University of Technology. Active years: 2012-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bernard Luke Flynn. Retrieved from https://idiyas.com/inventor/bernard-luke-flynn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27

% Patents Active = 70.4

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 59(Granted Patents)

Location History:

Vermont, AU (2012 - 2019)
Donvale, AU (2013 - 2021)

Company Filing History:

Ironwood Pharmaceuticals, Inc.

patents

1 out of 389

Beijing University of Technology

Central Adelaide Local Health Network Inc.

patents

6. 1 out of 49

University of South Australia

patents

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

Areas of Expertise:

Anxiolytic Compounds

Tubulin Polymerisation Inhibitors

Potassium Channel Blockers

Substituted Benzofurans

Benzothiophenes

Benzoselenophenes

Indoles

Chemical Processes

Small-Molecules

Naphthyridines

Furo[2,3-d]pyrimidines

Crystalline Forms

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10954231 - Anxiolytic compounds (2021-03-23),

2. 10266529 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2019-04-23),

3. 10233181 - Anxiolytic compounds (2019-03-19),

4. 10213409 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors (2019-02-26),

5. 9975892 - Anxiolytic compounds (2018-05-22),

6. 9828351 - Enzyme interacting agents (2017-11-28),

7. 9758516 - Crystalline form of an anxiolytic compound (2017-09-12),

8. 9745296 - Salts, co-crystals, and polymorphs of an anxiolytic compound (2017-08-29),

9. 9573945 - Anxiolytic compounds (2017-02-21),

10. 9346842 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors (2016-05-24),

11. 9133188 - Methods for preparing naphthyridines (2015-09-15),

12. 9023848 - Small-molecules as therapeutics (2015-05-05),

13. 8906912 - Anxiolytic compounds (2014-12-09),

14. 8716335 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors (2014-05-06),

15. 8680135 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors (2014-03-25),

Title: The Innovative Contributions of Bernard Luke Flynn in Pharmacology

Introduction

Bernard Luke Flynn, based in Vermont, Australia, is a distinguished inventor recognized for his significant contributions to pharmacology and therapeutic innovations. With an impressive portfolio of 27 patents, Flynn has made strides in developing anxiolytic compounds aimed at treating anxiety disorders and other central nervous system diseases.

Latest Patents

Among Flynn's latest inventions are groundbreaking patents focused on anxiolytic compounds. The first patent discusses chemical compounds of general formula (I) that may exhibit useful therapeutic activity for a variety of central nervous system disorders, particularly anxiety disorders. Additionally, he has patented crystalline forms and polymorphs of an anxiolytic compound, specifically the FUM-P3, FUM-P4, MLA-P3, and MLA-P4 forms. These inventions not only promise advancements in therapeutic applications but also provide methods for treating and preventing diseases, showcasing Flynn's commitment to innovative solutions in healthcare.

Career Highlights

Throughout his career, Flynn has been affiliated with prominent companies such as Bionomics Inc. and Ironwood Pharmaceuticals, Inc. His experience in these organizations has greatly influenced his research and patent development, enabling him to contribute effectively to the pharmaceutical industry.

Collaborations

Flynn has collaborated with notable professionals in his field, including Jonathan Bayldon Baell and Jason Hugh Chaplin. These partnerships have fostered a creative environment for exploring new therapeutic avenues and enhancing research outcomes.

Conclusion

Bernard Luke Flynn's innovative work in developing anxiolytic compounds highlights the importance of research and invention in addressing mental health issues. His extensive patent portfolio reflects his dedication to improving therapeutic options for central nervous system disorders, positioning him as a leading figure in the pharmaceutical innovation landscape. As he continues to advance his research, the potential for further contributions to the field remains substantial.

Profile summary based on public USPTO records.